Abbott/$ABT
1D1W1MYTD1Y5YMAX
Capital at risk
About Abbott
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
- Ticker
- $ABT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 115,000
- Headquarters
- Abbott Park, United States
- Website
- www.abbott.com
Abbott Metrics
BasicAdvanced
$177B
33.12
$3.09
0.58
$2.48
2.46%
Price and volume
Market cap
$177B
Beta
0.58
52-week high
$137.49
52-week low
$81.97
Average daily volume
7.7M
Dividend rate
$2.48
Financial strength
Current ratio
1.376
Quick ratio
0.797
Long term debt to equity
0.574
Total debt to equity
0.632
Dividend payout ratio (TTM)
78.54%
Interest coverage (TTM)
11.40%
Profitability
EBITDA (TTM)
11,867
Gross margin (TTM)
56.85%
Net profit margin (TTM)
11.65%
Operating margin (TTM)
17.68%
Effective tax rate (TTM)
27.77%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
5.33%
Return on equity (TTM)
10.58%
Valuation
Price to earnings (TTM)
33.12
Price to revenue (TTM)
3.826
Price to book
3.42
Price to tangible book (TTM)
-172.26
Price to free cash flow (TTM)
22.778
Free cash flow yield (TTM)
4.39%
Free cash flow per share (TTM)
4.494
Dividend yield (TTM)
2.42%
Forward dividend yield
2.46%
Growth
Revenue change (TTM)
8.06%
Earnings per share change (TTM)
-61.23%
3-year revenue growth (CAGR)
5.01%
10-year revenue growth (CAGR)
8.53%
3-year earnings per share growth (CAGR)
1.84%
10-year earnings per share growth (CAGR)
7.41%
3-year dividend per share growth (CAGR)
7.43%
10-year dividend per share growth (CAGR)
9.29%
What the Analysts think about Abbott
Analyst ratings (Buy, Hold, Sell) for Abbott stock.
Analyst projections of the future price of Abbott stock.
Bulls say / Bears say
Abbott beat second-quarter earnings and sales expectations and raised full-year 2026 adjusted EPS guidance to $5.45–$5.60, while reaffirming 6.5%–7.5% comparable sales growth. (Reuters)
Medical Devices delivered strong momentum, while demand in cancer diagnostics helped offset concerns about softer procedure volumes and supported Abbott’s profit outlook. (Reuters)
The Exact Sciences acquisition expands Abbott into oncology screening, treatment selection and disease monitoring, creating a potentially faster-growing diagnostics platform despite near-term dilution. (Abbott)
The $20.6 billion Exact Sciences acquisition was funded primarily with $20 billion of new long-term debt, while Abbott’s 2026 adjusted EPS guidance initially fell by $0.20 because of deal-related dilution. (Reuters)
Nutrition remains a material drag: second-quarter comparable sales declined 3.6%, including a 9.0% reported decline in U.S. sales, reflecting lower volumes and strategic pricing actions. (Abbott)
Abbott faces substantial product-liability uncertainty in preterm infant formula, including an approximately $670 million settlement announced in August 2026 involving NEC claims. (Abbott 8-K)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Abbott Financial Performance
Revenues and expenses
Abbott Earnings Performance
Company profitability
Upcoming events
No upcoming events
Abbott News
AllArticlesVideos
Abbott to pay $384 mln over contaminated infant formula allegations, US Justice Dept says
Reuters3 days ago
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
MarketBeat2 weeks ago
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
Reuters3 weeks ago
Funds containing Abbott
AllEURGBPUSD
Fund name | Fund size | $ABT weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.93% |
iShares AI Adopters and Applications€AIAA | €169M | 1.73% |
iShares AI Adopters and Applications£AIAA | £145M | 1.73% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.41% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.41% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.